Condition: Multiple Myeloma, Newly Diagnosed · Multiple Myeloma (MM) · Sponsor: SCRI Development Innovations, LLC
This is an open-label, multi-site, Phase II randomized trial with response-adaptive design for newly diagnosed multiple myeloma (NDMM) participants who have had prior induction therapy. The primary objective of this study is to compare the rates of achieving undetectable measurable residual disease (MRD) in the bone marrow with elranatamab and daratumumab employed as post-induction consolidation and maintenance treatment (Arm A) versus autologous stem cell transplant (ASCT) followed by lenalidomide and daratumumab treatment (Arm B).
This description comes directly from the study's public registry record.
Sarah Cannon Development Innovations, LLC · 1-844-710-6157 · SCRI.InnovationsMedical@scri.com
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| University of North Carolina | Chapel Hill, North Carolina, United States | Recruiting |
| Oncology Hematology Care | Cincinnati, Ohio, United States | Withdrawn |
| The Ohio State University- The James Cancer Hospital and Solove Research Institute | Columbus, Ohio, United States | Recruiting |
| SCRI Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| University of Texas Southwestern | Dallas, Texas, United States | Recruiting |
| Virginia Oncology Associates | Norfolk, Virginia, United States | Recruiting |
| University of Wisconsin Clinical Science Center | Madison, Wisconsin, United States | Recruiting |
| Medical College of Wisconsin | Milwaukee, Wisconsin, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06974786